Advances in eye health technology are redefining how beneficiaries will access eye care in 2021, and benefit managers can play an important role in supporting the emerging vision technologies—including gene therapy, sustained-release medications and remote monitoring—that have the potential to improve health outcomes, increase patient convenience and lower costs.
Gene therapies
Medicine continues to advance with new therapies, new procedures, new treatments and new medications. Though these advances are collectively often very effective, they also mean additional work for patients and physicians. This increased work is now referred to as "treatment burden," or how much work is involved in getting better.
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2025 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.